• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

III-VI

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

III-VI, News, Portfolio · September 25, 2019

Proteon Therapeutics and ArTara Therapeutics Agree to Combine

vonapanitase

September 23, 2019 Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing to be Led by a …

III-VI, News, Portfolio · June 4, 2017

Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase

vonapanitase

WALTHAM, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney …

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact